🔊CEOInterviews

Bradley Sitko on partnership deals

From Sara Jane Demy Interviews Brad Sitko at BioFuture 2023 · · Demy-Colton

“There are over 600 partnership deals like this done every year, so that means for us there's a big environment for us to be able to service and provide capital to. We unlock the innovation of tomorrow using the innovation that was created today.”

Bradley Sitko
Chief Investment Officer, XOMA ROYALTY CORP
Policy Impact partnership dealsinvestment opportunitiesinnovation financing

On , Bradley Sitko, Chief Investment Officer at XOMA ROYALTY CORP, spoke about partnership deals during Sara Jane Demy Interviews Brad Sitko at BioFuture 2023 on Demy-Colton.

Sara Jane Demy Interviews Brad Sitko at BioFuture 2023
Watch on YouTube
Sara Jane Demy Interviews Brad Sitko at BioFuture 2023
Demy-Colton
Watch on YouTube
This interview features Sara Jane Demy, Demy-Colton and Brad Sitko, XOMA. It followed the panel discussion "Mavericks: ...
Bradley Sitko

About Bradley Sitko

Chief Investment Officer · XOMA ROYALTY CORP

In a September 2024 interview at BioFuture 2023, Bradley Sitko, Chief Investment Officer at Xoma Royalty, discussed the company's royalty model and its role in the biotech financing landscape. Sitko explained that Xoma provides capital to biotech companies in exchange for future at-risk payments from existing partnership deals, describing this as a way to "unlock the innovation of tomorrow using the innovation that was created today." He noted that there are over 600 such partnership deals annually, creating a large market for Xoma's services. Sitko stated that Xoma has completed over a dozen royalty deals and built a portfolio of more than 70 assets. Sitko also commented on the broader biotech environment, saying that companies are "forced to reinvent themselves, to think differently, to spend prudently," which he described as "not a bad thing in the long run." He expressed the view that the industry is "closer to the end of the cycle than to the beginning" and predicted that a true turnaround would occur once there is stability in the macro picture within health and life sciences. Sitko characterized Xoma's approach as offering non-dilutive financing at a stage in a company's lifecycle where it "historically hasn't been available."

Profile compiled from Bradley Sitko's verified public interviews and appearances. See all quotes & transcripts →

More from Bradley Sitko XOMA ROYALTY CORP (XOMA) Full Transcript Explore All Executives